유럽 연합 -
아이슬란드어 -
EMA (European Medicines Agency)
inlyta
pfizer europe ma eeig - axitinib - krabbamein, nýrnafrumur - prótín nt-hemlar - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.